Juan Pedro Martinez-Barbera

Has grant

Professor

University College London
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Targeting cellular senescence against childhood high-grade glioma (TANGENTIAL)

Open Date: 2023-01-01

Close Date:

Grant: Close

Repurposing the alcohol-abuse drug disulfiram to target a key epigenetic hallmark of Diffuse Midline Glioma

Open Date: 2023-01-01

Close Date: 2026-01-01

Grant: Open

EVEREST 2.0; Paediatric research and Innovation centre for low-grade brain tumours

Open Date: 2022-01-01

Close Date: 2027-01-01

Grant: Close

Exploiting therapeutic targets in paediatric high grade gliomas with H3K27M mutations

Open Date: 2020-01-01

Close Date: 2024-01-01

Grant: Close

Characterisation of the pro-tumorigenic activities of cellular senescence in adamantinomatous craniopharyngioma and preclinical validation of novel therapies

Open Date: 2019-01-01

Close Date: 2026-01-01

Articles (7)

Year:

2025

Year:

2025

Year:

2023

Craniopharyngiomas (CPs) are clinically aggressive tumors because of their invasive behavior and recalcitrant tendency to recur after therapy. There are 2 types based on their distinct histology and molecular features: the papillary craniopharyngioma (PCP), which is associated with BRAF-V600E mutations and the adamantinomatous craniopharyngioma (ACP), characterized by mutations in CTNNB1 (encoding β-catenin). Patients with craniopharyngioma show symptoms linked to the location of the tumor close to the optic pathways, hypothalamus, and pituitary gland, such as increased intracranial pressure, endocrine deficiencies, and visual defects. Treatment is not specific and mostly noncurative, and frequently includes surgery, which may achieve gross total or partial resection, followed by radiotherapy. In cystic tumors, frequent drainage is often required and intracystic instillation of drugs has been used to help manage cyst refilling. More recently targeted therapies have been used, particularly in PCP, but also now in ACP and clinical trials are underway or in development. Although patient survival is high, the consequences of the tumor and its treatment can lead to severe comorbidities resulting in poor quality of life, in particular for those patients who bear tumors with hypothalamic involvement. Accordingly, in these patients at risk for the development of a hypothalamic syndrome, hypothalamus-sparing treatment strategies such as limited resection followed by irradiation are recommended. In this review, we provide an update on various aspects of CP, with emphasis on recent advances in the understanding of tumor pathogenesis, clinical consequences, management, and therapies.

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (1)

John Apps

University of Birmingham

UNITED KINGDOM
View details